Navigation Links
Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
Date:1/28/2008

TORONTO, Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced it has completed its Pre-IND (Investigational New Drug) meeting with the FDA to discuss the upcoming IND submission for ARH460-16-2, its lead CD44 Cancer Stem Cell Program. ARH460-16-2 is an anti-cancer antibody targeting a novel epitope of CD44 found in hematological and solid cancers, including breast, colon and prostate. The Pre-IND meeting focused on development plans for the drug, including manufacturing details, preclinical pharmacology and toxicology data, and the proposed plans for the Phase I clinical program.

"The completion of our pre-IND meeting with the FDA is an important milestone for the Company and demonstrates the significant progress we have made with our lead CD44 Cancer Stem Cell Program and our ability to advance drug candidates towards human clinical trials," said Dr. David Young, President and Chief Executive Officer. "We are pleased with the outcome of this meeting and will continue to prepare for our IND submission with the intention of initiating human clinical trials this year."

Concurrently, ARIUS announced the promotion of Susan Hahn, PhD, formerly Director of Development, to the position of Vice President of Development. "Dr. Hahn has been instrumental in leading the development of our antibody programs that we are taking to the clinic," said Dr. Young. "In her new role, Dr. Hahn will continue to focus on meeting ARIUS' development milestones as we move each of our lead drug candidates towards human clinical trials."

The CD44 Cancer Stem Cell program was generated using ARIUS' proprietary FunctionFIRST(TM) technology, which selects antibodies based on their ability to kill cancer cells. Pre-clinical data from a dose-ranging pilot toxicology study in non-human primate models demonstrated no dose-limiting toxic effects at doses up
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
4. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. ARIUS to present at Chinese Global Financial Forum
7. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
8. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
9. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
10. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
11. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... added to the growing case for graphene being ... thing in the high-tech world by the two-dimensional ... of researchers led by a scientist with the ... Laboratory (Berkeley Lab) has reported the first experimental ... materials. The recorded charge transfer time clocked in ...
(Date:8/26/2014)... , Aug. 26, 2014   Lycera ... of breakthrough oral medicines to treat autoimmune disease ... modulation, today announced the appointment of Harinder ... scientific advisory board.  Dr. Singh will lead the ... advance Lycera,s multiple ongoing research programs and pipeline ...
(Date:8/26/2014)... Switzerland (PRWEB) August 26, 2014 ... for drug discovery and life science research, today ... Meetings will be held in Asia, Europe, ... from global pharmaceutical companies and leading research organizations ... share best practices, case studies, and upcoming challenges ...
(Date:8/26/2014)... YORK , Aug. 26, 2014  That,s Nice ... science markets, today announced the formation of a new ... content development. The expanded team will combine current and ... areas at That,s Nice. Guy ... Content to lead the team. Tiene was previously Director ...
Breaking Biology Technology:Competition for graphene 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3
... , , , , , , , , ... leading provider of biopharmaceutical products in China, announced today,that it has ... commence a human clinical trial for its vaccine,against human enterovirus 71 ... the first clinical trial application for HFMD vaccine,submitted in China. , ...
... SBS , CALGARY, Dec. 24 /PRNewswire-FirstCall/ - SemBioSys Genetics ... on plant-produced Apo AI(Milano) in light of the Apo ... Company, of Parsippany, New Jersey. , "The Medicines Company,s ... program is a strong endorsement of Apo AI(Milano) and ...
... to dye the Chicago River green on St. Patrick,s Day. ... scenes. And now researchers at Northwestern University have used it ... useful tool is the dye fluorescein, and Jiaxing Huang, assistant ... of Engineering and Applied Science, and his research group have ...
Cached Biology Technology:Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4SemBioSys updates progress on Apo AI(Milano) 2SemBioSys updates progress on Apo AI(Milano) 3An easy way to see the world's thinnest material 2
(Date:8/25/2014)... and efficient cell separation from a device the size ... tilt-angle standing surface acoustic waves, according to a team ... do cell separation before analysis," said Tony Jun Huang, ... separation process affects the integrity of the cells, damages ... well.", Tilted-angle standing surface acoustic waves can separate cells ...
(Date:8/25/2014)... Fire and Emergency Services of Western Australia, a bushfire ADVICE ... kilometres east of Broome, and Cape Leveque Road approximately 40 ... There is no threat to lives or homes but there ... is a complex of fires burning in the area on ... The fires are also burning on the eastern side ...
(Date:8/25/2014)... 2014  Scribe Labs unveiled its first product, ... saw its campaign surpass the $50,000 funding goal ... metrics that help an athlete understand how factors ... running mechanics. Built with an advanced 9-axis integrated ... advanced set of running metrics available outside of ...
Breaking Biology News(10 mins):Tilted acoustic tweezers separate cells gently 2runScribe Fitness Wearable Exceeds 200% of Kickstarter Goal in First Week 2
... other biological molecules, only exist today in a few ... Tom Ran and Shai Kaplan, research students in the ... Biological Chemistry, and Computer Science and Applied Mathematics Departments ... devices ,user friendly, even while performing complex computations and ...
... 30 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE ... reported financial results for its second quarter ended June 30, 2009. ... quarter of 2009 were $5.8 million, a decrease of 7% compared ... the six months ended June 30, 2009, revenues decreased 14% to ...
... GEOLOGY studies include some curious associations: air hockey and ... Basalts and the Congo Fan; and rock hyrax middens ... on Mars; the only basin known to have both ... fish die-off; and mapping naturally occurring asbestos in the ...
Cached Biology News:DNA computation gets logical at the Weizmann Institute of Science 2Aware, Inc. Reports Second Quarter 2009 Financial Results 2Aware, Inc. Reports Second Quarter 2009 Financial Results 3Aware, Inc. Reports Second Quarter 2009 Financial Results 4Aware, Inc. Reports Second Quarter 2009 Financial Results 5Aware, Inc. Reports Second Quarter 2009 Financial Results 6Aware, Inc. Reports Second Quarter 2009 Financial Results 7Aware, Inc. Reports Second Quarter 2009 Financial Results 8August 2009 Geology and GSA Today media highlights 2August 2009 Geology and GSA Today media highlights 3August 2009 Geology and GSA Today media highlights 4August 2009 Geology and GSA Today media highlights 5August 2009 Geology and GSA Today media highlights 6August 2009 Geology and GSA Today media highlights 7August 2009 Geology and GSA Today media highlights 8August 2009 Geology and GSA Today media highlights 9August 2009 Geology and GSA Today media highlights 10August 2009 Geology and GSA Today media highlights 11August 2009 Geology and GSA Today media highlights 12August 2009 Geology and GSA Today media highlights 13August 2009 Geology and GSA Today media highlights 14August 2009 Geology and GSA Today media highlights 15
ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Rat PTX2/SAP...
Biology Products: